Literature DB >> 12930093

Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli.

Amulya K Panda1.   

Abstract

Escherichia coli has been most extensively used for the large-scale production of therapeutic proteins, which do not require complex glycosylation for bioactivity. In recent years tremendous progress has been made on the molecular biology, fermentation process development and protein refolding from inclusion bodies for efficient production of therapeutic proteins using E. coli. High cell density fermentation and high throughput purification of the recombinant protein from inclusion bodies of E. coli are the two major bottle necks for the cost effective production of therapeutic proteins. The aim of this review is to summarize the developments both in high cell density, high productive fermentation and inclusion body protein refolding processes using E. coli as an expression system. The first section deals with the problems of high cell density fermentation with an aim to high volumetric productivity of recombinant protein. Process engineering parameters during the expression of ovine growth hormone as inclusion body in E. coli were analyzed. Ovine growth hormone yield was improved from 60 mg L(-1) to 3.2 g L(-1) using fed-batch culture. Similar high volumetric yields were also achieved for human growth hormone and for recombinant bonnet monkey zona pellucida glycoprotein expressed as inclusion bodies in E. coli. The second section deals with purification and refolding of recombinant proteins from the inclusion bodies of E. coli. The nature of inclusion body protein, its characterization and isolation from E. coli has been discussed in detail. Different solubilization and refolding methods, which have been used to recover bioactive protein from inclusion bodies of E. coli have also been discussed. A novel inclusion body protein solubilization method, while retaining the existing native-like secondary structure of the protein and its subsequent refolding in to bioactive form, has been discussed. This inclusion body solubilization and refolding method has been applied to recover bioactive recombinant ovine growth hormone, recombinant human growth hormone and bonnet monkey zona pellucida glycoprotein from the inclusion bodies of E. coli.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12930093     DOI: 10.1007/3-540-36466-8_3

Source DB:  PubMed          Journal:  Adv Biochem Eng Biotechnol        ISSN: 0724-6145            Impact factor:   2.635


  24 in total

1.  Localization of functional polypeptides in bacterial inclusion bodies.

Authors:  Elena García-Fruitós; Anna Arís; Antonio Villaverde
Journal:  Appl Environ Microbiol       Date:  2006-11-03       Impact factor: 4.792

2.  Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague.

Authors:  Jeremy L Goodin; David F Nellis; Bradford S Powell; Vinay V Vyas; Jeffrey T Enama; Lena C Wang; Patrick K Clark; Steven L Giardina; Jeffery J Adamovicz; Dennis F Michiel
Journal:  Protein Expr Purif       Date:  2006-12-31       Impact factor: 1.650

3.  Optimizing of Nutrients for High Level Expression of Recombinant Streptokinase Using pET32a Expression System.

Authors:  Shima Mahmoudi; Hamid Abtahi; Abbas Bahador; Ghasem Mosayebi; Ali Hatef Salmanian; Mostafa Teymuri
Journal:  Maedica (Buchar)       Date:  2012-09

4.  Immunogenicity of Escherichia coli expressed envelope 2 protein of Chikungunya virus.

Authors:  Nagesh K Tripathi; Raj Priya; Ambuj Shrivastava
Journal:  Bioengineered       Date:  2014-02-27       Impact factor: 3.269

5.  Reduction of N-terminal methionylation while increasing titer by lowering metabolic and protein production rates in E. coli auto-induced fed-batch fermentation.

Authors:  Jianlin Xu; Yueming Qian; Paul M Skonezny; Li You; Zizhuo Xing; David S Meyers; Robert J Stankavage; Shih-Hsie Pan; Zheng Jian Li
Journal:  J Ind Microbiol Biotechnol       Date:  2012-04-20       Impact factor: 3.346

6.  Efficient production of active chicken avidin using a bacterial signal peptide in Escherichia coli.

Authors:  Vesa P Hytönen; Olli H Laitinen; Tomi T Airenne; Heidi Kidron; Niko J Meltola; Eevaleena J Porkka; Jarno Hörhä; Tiina Paldanius; Juha A E Määttä; Henri R Nordlund; Mark S Johnson; Tiina A Salminen; Kari J Airenne; Seppo Ylä-Herttuala; Markku S Kulomaa
Journal:  Biochem J       Date:  2004-12-01       Impact factor: 3.857

7.  Production of tag-free recombinant fusion protein encompassing promiscuous T cell epitope of tetanus toxoid and dog zona pellucida glycoprotein-3 for contraceptive vaccine development.

Authors:  Neha Gupta; Abhinav Shrestha; Amulya Kumar Panda; Satish Kumar Gupta
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

Review 8.  Production of recombinant proteins in E. coli by the heat inducible expression system based on the phage lambda pL and/or pR promoters.

Authors:  Norma A Valdez-Cruz; Luis Caspeta; Néstor O Pérez; Octavio T Ramírez; Mauricio A Trujillo-Roldán
Journal:  Microb Cell Fact       Date:  2010-03-19       Impact factor: 5.328

9.  An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli.

Authors:  José M Aguilar-Yáñez; Roberto Portillo-Lara; Gonzalo I Mendoza-Ochoa; Sergio A García-Echauri; Felipe López-Pacheco; David Bulnes-Abundis; Johari Salgado-Gallegos; Itzel M Lara-Mayorga; Yenny Webb-Vargas; Felipe O León-Angel; Ramón E Rivero-Aranda; Yuriana Oropeza-Almazán; Guillermo M Ruiz-Palacios; Manuel I Zertuche-Guerra; Rebecca M DuBois; Stephen W White; Stacey Schultz-Cherry; Charles J Russell; Mario M Alvarez
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

10.  Size characterization of inclusion bodies by sedimentation field-flow fractionation.

Authors:  Gerd Margreiter; Paul Messner; Karin D Caldwell; Karl Bayer
Journal:  J Biotechnol       Date:  2008-08-08       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.